Literature DB >> 12915129

The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness.

Piera Maggiora1, Annalisa Lorenzato, Stefano Fracchioli, Barbara Costa, Massimo Castagnaro, Riccardo Arisio, Dionyssios Katsaros, Marco Massobrio, Paolo M Comoglio, Maria Flavia Di Renzo.   

Abstract

RON is a member of the receptor tyrosine kinase gene family that includes the MET oncogene, whose germline mutations have been causally related to human tumorigenesis. In vitro, RON and MET receptors cross-talk, synergize in intracellular signaling, and cooperate in inducing morphogenic responses. Here we show that the RON and MET oncogenes were expressed in 55% and 56% of human ovarian carcinomas, respectively, and were significantly coexpressed in 42% (P < 0.001). In ovarian carcinoma samples and cell lines we did not find mutations in RON and MET gene kinase domain, nor coexpression of RON and MET receptor ligands (MSP and HGF, respectively). We show that motility and invasiveness of ovarian cancer cells coexpressing MET and RON receptors were elicited by HGF and, to a lesser extent, by MSP. More interestingly, invasion of both reconstituted basement membrane and collagen gel was greatly enhanced by the simultaneous addition of the two ligands. These data suggest that coexpression of the MET and RON receptors confer a selective advantage to ovarian cancer cells and might promote ovarian cancer progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12915129     DOI: 10.1016/s0014-4827(03)00250-7

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  37 in total

1.  Ron receptor overexpression in the murine prostate induces prostate intraepithelial neoplasia.

Authors:  Jerilyn K Gray; Andrew M Paluch; William D Stuart; Susan E Waltz
Journal:  Cancer Lett       Date:  2011-09-24       Impact factor: 8.679

2.  Isolation of Fully Human Antagonistic RON Antibodies Showing Efficient Block of Downstream Signaling and Cell Migration.

Authors:  Zeynep Gunes; Adriana Zucconi; Mario Cioce; Annalisa Meola; Monica Pezzanera; Stefano Acali; Immacolata Zampaglione; Valeria De Pratti; Luca Bova; Fabio Talamo; Anna Demartis; Paolo Monaci; Nicola La Monica; Gennaro Ciliberto; Alessandra Vitelli
Journal:  Transl Oncol       Date:  2011-02-01       Impact factor: 4.243

Review 3.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

4.  Four individually druggable MET hotspots mediate HGF-driven tumor progression.

Authors:  Cristina Basilico; Anna Hultberg; Christophe Blanchetot; Natalie de Jonge; Els Festjens; Valérie Hanssens; Sjudry-Ilona Osepa; Gitte De Boeck; Alessia Mira; Manuela Cazzanti; Virginia Morello; Torsten Dreier; Michael Saunders; Hans de Haard; Paolo Michieli
Journal:  J Clin Invest       Date:  2014-05-27       Impact factor: 14.808

5.  Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.

Authors:  Zhenfu Han; Peter K W Harris; Darin E Jones; Ryan Chugani; Tommy Kim; Manjula Agarwal; Wei Shen; Scott A Wildman; James W Janetka
Journal:  ACS Med Chem Lett       Date:  2014-10-09       Impact factor: 4.345

Review 6.  Tumor-stroma interactions.

Authors:  Neil A Bhowmick; Harold L Moses
Journal:  Curr Opin Genet Dev       Date:  2005-02       Impact factor: 5.578

7.  Prognostic significance of MST1R dysregulation in renal cell tumors.

Authors:  Ana S Pires-Luís; Márcia Vieira-Coimbra; Maria João Ferreira; João Ramalho-Carvalho; Pedro Costa-Pinheiro; Luís Antunes; Paula C Dias; Francisco Lobo; Jorge Oliveira; Inês Graça; Rui Henrique; Carmen Jerónimo
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

8.  Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion.

Authors:  Nikki Cheng; Anna Chytil; Yu Shyr; Alison Joly; Harold L Moses
Journal:  Mol Cancer Res       Date:  2008-10       Impact factor: 5.852

Review 9.  Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.

Authors:  Purnima K Wagh; Belinda E Peace; Susan E Waltz
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

10.  Expression of the RON receptor tyrosine kinase and its association with gastric carcinoma versus normal gastric tissues.

Authors:  Donghui Zhou; Gang Pan; Chen Zheng; Jingjing Zheng; Liping Yian; Xiaodong Teng
Journal:  BMC Cancer       Date:  2008-11-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.